Background
There remains uncertainty about the optimum timing of antiretroviral therapy (ART) initiation in HIV-positive people with cryptococcal meningitis. This uncertainty is the result of conflicting data on the mortality risk and occurrence of immune reconstitution inflammatory syndrome (IRIS) when ART is initiated less than four weeks after cryptococcal meningitis treatment is commenced.
Objectives
To compare the outcomes of early initiation of ART (less than four weeks after starting antifungal treatment) versus delayed initiation of ART (four weeks or more after starting antifungal treatment) in HIV-positive people with concurrent cryptococcal meningitis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase for trials published between 1 January 1980 and 7 August 2017. We additionally searched international trial registries, including ClinicalTrials.gov and WHO International Clinical Trials Registry Platform (ICTRP), and conference abstracts from the International AIDS Society (IAS) and the Conference on Retroviruses and Opportunistic Infections (CROI) for ongoing or unpublished studies between 2015 and 2017. We reviewed reference lists of included studies to identify additional studies.
Selection criteria
We included randomized controlled trials (RCTs) that compared early versus delayed ART initiation in HIV-positive people with cryptococcal meningitis. Children, adults, and adolescents from any setting were eligible for inclusion.
Two review authors independently applied the inclusion criteria and extracted data. We presented dichotomous outcomes as risk ratios (RR) with 95% confidence intervals (CIs). We presented time-to-death data as hazard ratios with 95% CIs. We assessed the certainty of the evidence using the GRADE approach.
Main results
Four trials including 294 adult participants met the inclusion criteria of this review. Participants were predominantly from low-and middle-income countries. Two trials treated cryptococcal meningitis with amphotericin B and fluconazole; a third trial used fluconazole monotherapy; and the fourth trial did not specify the antifungal used.
Early ART initiation may increase all-cause mortality compared to delayed ART initiation (RR 1.42, 95% CI 1.02 to 1.97; 294 participants, 4 trials; low-certainty evidence). Early ART initiation may reduce relapse of cryptococcal meningitis compared to delayed ART initiation (RR 0.27, 95% CI 0.07 to 1.04; 205 participants, 2 trials, low-certainty evidence). We are uncertain whether early ART initiation increases or reduces cryptococcal IRIS events compared to delayed ART initiation (RR 3.56, 95% CI 0.51 to 25.02; 205 participants, 2 trials; I 2 = 54%; very low-certainty evidence). We are uncertain if early ART initiation increases or reduces virological suppression at six months compared to delayed ART initiation (RR 0.93, 95% CI 0.72 to 1.22; 205 participants, 2 trials; I 2 statistic = 0%; very low-certainty evidence).
We were unable to pool results related to rate of fungal clearance for the two trials that reported this outcome; individual trial results indicated that there was no difference in cerebrospinal fluid fungal clearance between trial arms. Similarly, we were unable to pool results on adverse events for the trials reporting on this outcome; individual trial results indicated no difference in the occurrence of grade 3 to 5 adverse events between trial arms.
Three of the four included trials had an overall low or unclear risk of bias related to the primary outcome of all-cause mortality. However, we assessed one trial as at high risk of bias due to selective outcome reporting and other bias. This, in addition to the few clinical events and imprecision of effect estimates, led to downgrading of the evidence to low or very low certainty.
Authors' conclusions
The results of this review are relevant to HIV-positive adults with cryptococcal meningitis in low-and middle-income countries. These data suggest a higher risk of mortality among people who initiate ART within four weeks of cryptococcal meningitis diagnosis. However, it is unclear if this higher mortality risk is related to cryptococcal meningitis-IRIS.
P L A I N L A N G U A G E S U M M A R Y

Timing of antiretroviral therapy initiation in HIV-positive people with cryptococcal meningitis
What is the aim of this review?
The aim of this Cochrane Review was to determine whether initiating antiretroviral therapy (ART) within four weeks of cryptococcal meningitis diagnosis resulted in a higher risk of dying or developing other complications than waiting more than four weeks to initiate ART.
Key messages
Initiating ART within four weeks of cryptococcal meningitis diagnosis may result in more deaths than initiating ART after four weeks. However, initiating ART early may result in a reduction in relapses of cryptococcal meningitis after adequate treatment. There was insufficient evidence to answer questions related to other complications.
What was studied in the review?
Cryptococcal meningitis is a fungal infection of the brain and the membranes covering the brain that occurs most frequently in people with weakened immune systems, such as people who are HIV-positive. Some studies have shown that HIV-positive people who start ART soon after initiating cryptococcal meningitis treatment (within four weeks) may deteriorate and die more frequently than those who delay treatment for a longer period (more than four weeks). This higher risk of death in the early ART group has been attributed to the occurrence of a condition called immune reconstitution inflammatory syndrome (IRIS). When ART is initiated, HIV-positive people with underlying infections such as cryptococcal meningitis may paradoxically develop a deterioration in their condition as their
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Early ART compared to delayed ART initiation in HIV-positive people with cryptococcal meningitis Patient or population: HIV-positive people with cryptococcal m eningitis Setting: global Intervention: early ART initiation (less than 4 weeks af ter initiation of cryptococcal m eningitis treatm ent) Comparison: delayed ART initiation (m ore than 4 weeks af ter initiation of cryptococcal m eningitis treatm ent)
Outcomes
Anticipated absolute effects * (95% CI) Relative effect (95% CI)
Number of participants (trials)
Certainty of the evidence (GRADE) We are uncertain as to whether or not early ART initiation increases or reduces virological suppression at 6
Comments
Risk with delayed ART Risk with early ART
B A C K G R O U N D
HIV/AIDS remains one of the world's most significant public health challenges, particularly in low-and middle-income countries. Antiretroviral therapy (ART) has substantially improved HIV prognosis by reducing associated morbidity and mortality. However uncertainty remains as to the optimal time for ART initiation when an HIV-positive person is co-infected with an opportunistic infection, particularly cryptococcal meningitis.
Description of the condition
Cryptococcal meningitis is an important opportunistic AIDSdefining infection and a major contributor to high mortality before and after ART is initiated (Bicanic 2005; WHO 2013 
Description of the intervention
The treatment of cryptococcal meningitis is usually initiated with a combination of antifungal agents (induction phase) followed by a single oral antifungal (consolidation phase) (NIH 2017a; NIH 2017b; WHO 2018) . The preferred induction regimen is amphotericin B combined with flucytosine, followed by oral flucona-zole for the consolidation phase, and until immune reconstitution on ART. Current guidelines recommend initiating ART within four to six weeks after cryptococcal meningitis treatment has commenced (WHO 2018).
How the intervention might work
There remains uncertainty as to when ART should be initiated in people with cryptococcal meningitis. This is related to reports of higher mortality rates among patients who initiate ART early in cryptococcal meningitis treatment (Njei 2013). Immune reconstitution inflammatory syndrome (IRIS), an exaggerated inflammatory response that can cause a paradoxical clinical deterioration soon after ART initiation, has frequently been described in association with cryptococcal meningitis. Some reports suggest that IRIS may contribute to higher mortality among HIV-positive people who initiate ART early after a cryptococcal meningitis diagnosis as compared to starting later, however there is no clear evidence of such an association (Bicanic 2009; Müller 2010; Shelburne 2005) . Additionally, in many settings where cryptococcal meningitis is prevalent, amphotericin B and flucytosine are unavailable due to resource constraints. In such settings the use of suboptimal cryptococcal meningitis treatment regimens with inadequate fungal clearance may put patients at increased risk of developing relapses and IRIS (Bicanic 2006; Loyse 2013) . Immune reconstitution inflammatory syndrome related to cryptococcal disease has been defined as events occurring within 12 months of ART initiation, reintroduction, or regimen switching after previous failure manifesting clinically as worsening disease with one or more inflammatory manifestations of cryptococcosis (meningitis, lymphadenopathy, intracranial space-occupying lesion or lesions, multifocal disease, cutaneous or soft-tissue lesions, pneumonitis, or pulmonary nodules) (Haddow 2010). Although many recommendations support delaying ART initiation in people with cryptococcal meningitis (NIH 2017a; WHO 2018), delaying ART for long periods may increase the risk of death or the development of other opportunistic infections (Lundgern 2015).
Why it is important to do this review
Studies that have evaluated the impact of timing of ART initiation in cryptococcal meningitis on mortality have, to date, had mixed results. Most cohort studies have shown no association between ART timing and mortality (Crabtree Ramírez 2017; Ingle 2015; Manosuthi 2008). However, these cohort studies were underpowered and limited by the inherent methodological issues with the cohort study design (Table 1) . A previous Cochrane Review suggested that there was insufficient evidence in support of either early or delayed initiation of ART (Njei 2013).
Determining when ART should be initiated after a diagnosis of cryptococcal meningitis involves balancing the survival benefit conferred by ART against the risk of IRIS. Conflicting data regarding the relationship between the timing of ART for cryptococcal meningitis and the high mortality pose a therapeutic dilemma, and studies to date have had variable results. We aimed to incorporate recent randomized controlled trials and to update the findings from the earlier review by Njei 2013.
O B J E C T I V E S
To compare the outcomes of early initiation ART (less than four weeks after starting antifungal treatment) versus delayed initiation of ART (four weeks or more after starting antifungal treatment) in HIV-positive people with concurrent cryptococcal meningitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
HIV-positive children, adolescents, and adults with cryptococcal meningitis.
Types of interventions
Early initiation of ART (ART initiated within four weeks of starting antifungal treatment) versus delayed initiation of ART (ART initiated at least four weeks after starting antifungal treatment).
Types of outcome measures
Primary outcomes
• All-cause mortality
Secondary outcomes
• Cryptococcal meningitis relapse • Recurrence of cryptococcal meningitis symptoms in previously laboratory-confirmed episode of cryptococcal meningitis, with resolution of symptoms for one month after treatment with participants being adherent to antifungal therapy, and now presenting with CSF antigen test or culture positive for C neoformans.
• 
Search methods for identification of studies
We identified all relevant trials regardless of language or publication status.
Electronic searches
We searched the following databases: 
Other sources
We checked the reference lists of existing reviews and all trials identified for other potentially relevant trials.
Data collection and analysis
We conducted data collection and analysis following methods recommended in the Cochrane Handbook for Systematic Reviews of Interventions and the Methodological Expectations for the Conduct of Cochrane Intervention Reviews (MECIR) (Higgins 2011; Higgins 2016).
Selection of studies
Two review authors (MPO and IEW) independently screened the titles and abstracts of all citations identified by searches against our inclusion criteria based on types of studies, interventions, participants, and outcomes. Both review authors evaluated the fulltext articles for inclusion. Where there was uncertainty about the inclusion of a trial, we consulted a third review author (TB).
Data extraction and management
We piloted and then finalized a data extraction tool. Two review authors (MPO and IEW) independently completed data extraction for the included trials and discussed discrepancies. In case of disagreement, we consulted a third review author (TB). For dichotomous outcomes, we extracted the number of participants who experienced the event and the number of participants randomized to each treatment group. For time-to-event outcomes, we extracted HRs and confidence intervals (CIs).
Assessment of risk of bias in included studies
Two review authors (MPO and IEW) independently assessed the risk of bias for each trial using the Cochrane 'Risk of bias' assessment tool (Higgins 2011). We contacted trial authors for missing information or clarification, but did not receive any responses to these queries. Two review authors independently applied the 'Risk of bias' criteria to each trial, resolving any differences in opinion through discussion or by consulting a third review author (MR). We assessed the risk of bias across six domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential biases (Higgins 2011). For each domain, we assigned a judgement of either low, high, or unclear risk of bias.
Measures of treatment effect
We presented dichotomous data using risk ratios (RR) with 95% CIs. We used intention-to-treat analyses for all dichotomous data. We presented time-to-event data using HRs with CIs.
Unit of analysis issues
No cluster-RCTs or trials with more than one intervention arm met the inclusion criteria of this review.
Dealing with missing data
Where a trial publication provided insufficient data, we contacted the trial authors to request the additional data (Bisson 2013; Makadzange 2010). For analyses with persistent missing data, we used available-case analysis and examined the robustness of this approach by examining best-and worse-case scenarios. Bisson 2013 provided an HR with 95% CI that was not available in the published manuscript; the method the authors used to generate this HR is uncertain.
Assessment of heterogeneity
We assessed the degree of heterogeneity by a visual inspection of forest plots and by examining the Chi 2 test. We quantified the extent of heterogeneity by calculating an estimation of the I 2 statistic. We followed the guidance outlined in Section 9.5.2 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
• 0% to 40%: might not be important • 30% to 60%: may represent moderate heterogeneity • 50% to 90%: may represent substantial heterogeneity • 75% to 100%: considerable heterogeneity
Where heterogeneity was present in pooled effect estimates, we explored possible reasons for variability by conducting subgroup analyses. Due to the limited number of trials and participants contributing to each outcome, we were restricted in the number of subgroup analyses we could conduct.
Assessment of reporting biases
We assessed publication bias qualitatively based on the characteristics of the included trials. There were insufficient trials to construct a funnel plot.
Data synthesis
We performed analyses using Review Manager 5 (RevMan 2014). When trials were considered clinically and methodologically comparable, we conducted meta-analyses using a random-effects model. We presented narrative results of outcomes only if there was insufficient data for a meta-analysis. For time-to-event data, we used HRs and CIs to generate log HRs and standard errors and used the generic inverse-variance method to analyse these data.
Certainty of the evidence
We assessed the certainty of the evidence for each outcome using the GRADE approach (Guyatt 2008), which defines the certainty of the evidence for each outcome as "the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest" (Higgins 2011). The GRADE certainty rating has four levels: high, moderate, low, or very low. We initially categorized RCTs as high-certainty evidence, and downgraded the certainty of the evidence after assessment of five criteria: risk of bias, consistency, directness, imprecision, and publication bias (Guyatt 2011). Two review authors (IEW and MPO) independently performed this assessment, resolving any disagreements by discussion. We constructed 'Summary of findings' tables and GRADE evidence tables to present the results of primary and secondary outcomes. We used GRADEpro GDT software to generate the 'Summary of findings' tables (GRADEpro GDT 2015) .
Subgroup analysis and investigation of heterogeneity
We had initially intended to conduct subgroup analyses for the primary outcome to investigate heterogeneity produced by antifungal drug treatment, geographical region, Glasgow coma score at randomization, and CSF white blood cell count. Due to limited data, we only conducted a subgroup analysis by antifungal drug treatment.
Sensitivity analysis
We used sensitivity analyses to assess the robustness of results. Where data were missing, we assessed best-and worst-case scenarios to determine the possible impact of missing data on the overall effect estimates. For the cryptococcal IRIS outcome, those participants who died in the early ART and delayed ART groups may not have been missing completely at random, therefore the assumption in the main analysis (available-case analysis) may be flawed. In addition, using an intention-to-treat analysis would suggest that all those who died would not have developed IRIS. We therefore conducted sensitivity analyses to determine the influence of different risks for IRIS among those who died before they could have received ART or developed IRIS. To evaluate this, we applied a best-case scenario (8% of those who died in the early ART group would have developed IRIS and 46% of those who died in the delayed ART group would have developed IRIS) and a worst-case scenario (46% of those who died in the early ART group would have developed IRIS and 8% of those who died in the delayed ART group would have developed IRIS). This was based on the range of reported incidence (8% to 46%) of paradoxical cryptococcal IRIS (Haddow 2010). Viral load results were only available for a subset of participants in the two trials that reported on this outcome. For our current analysis we assumed these participants to be missing completely at random, however it is possible that participants who died before they received ART or who did not have viral load measurements done despite receiving ART differed from those who had results. We applied best-and worst-case scenarios to these estimates to examine our results. These estimates were based on the range of viral load suppression rates (50% to 89%) reported by Joint United Nations Programme on HIV/AIDS (UNAIDS) for Eastern and sub-Saharan Africa (UNAIDS 2017).
R E S U L T S
Description of studies
Four trials met the inclusion criteria for this review (Bisson 2013; Boulware 2014; Makadzange 2010; Zolopa 2009). See Table 2 , the 'Characteristics of included studies' tables, and the 'Characteristics of excluded studies' tables for trial details.
Results of the search
We searched for trials published between 1 January 1980 and 7 August 2017. The search results are presented in a PRISMA flow diagram ( Figure 1 ). The electronic searches identified 314 titles and abstracts (80 from clinical trial registries, 180 from routine databases, and 54 from conference abstracts). After de-duplication, 273 records underwent title and abstract screening. We identified 13 records for full-text eligibility screening. We excluded seven of these records with reasons (two further duplicates, two journal correspondence, three wrong study design). We included six records representing four trials in the qualitative and quantitative synthesis. 
Included studies
We have provided a summary of the included trials in Table 2 and further individual trial details in the 'Characteristics of included studies' tables.
Participants
The Zolopa 2009 trial included participants with several different types of opportunistic infections and did not disaggregate information for those with cryptococcal meningitis, therefore limited descriptive data could be provided for this trial.
Setting
We included four trials with 294 participants from Botswana, Puerto Rico, South Africa, Uganda, the USA, and Zimbabwe. Trials were conducted between May 2003 and November 2011.
Demographic characteristics
We did not identify any studies conducted in children less than 13 years old. Most trials included only adults aged more than 18 or 21 years, except Zolopa 2009, which also included adolescents aged 13 years and over. Approximately 50% of participants were male in Boulware 2014, Bisson 2013, and Makadzange 2010. The median or mean age ranged from 35 to 38 years.
All trials included participants who were HIV-positive and had a diagnosis of cryptococcal meningitis or other opportunistic infection (Zolopa 2009).
Exclusion criteria
Previous or current ART use was an exclusion criterion for all trials. All trials except Zolopa 2009 further excluded pregnancy/ lactation and concurrent central nervous system infections such as bacterial meningitis.
Intervention and comparison
Antifungal therapy
Antifungal treatment regimens differed markedly between trials. Two trials used a combination of amphotericin B and fluconazole in the induction and consolidation antifungal regimen (Bisson 2013; Boulware 2014); one trial used fluconazole only (Makadzange 2010); and one trial did not report on the antifungal regimen (Zolopa 2009). Bisson 2013 provided amphotericin B (0.7 mg/kg/day) for two weeks, followed by oral fluconazole 400 mg daily for eight weeks. Boulware 2014 administered two weeks of amphotericin B (0.7 to 1.0 mg/kg/day) combined with fluconazole (800 mg/day) followed by 800 mg of fluconazole per day for at least three weeks or until a CSF culture was sterile, followed by 400 mg of fluconazole per day thereafter, for a total consolidation period of at least 12 weeks. Makadzange 2010 used fluconazole 800 mg daily for 10 weeks. These three trials also reported prescribing secondary prophylaxis of 200 mg of fluconazole per day after the induction and consolidation phases of antifungal treatment. Boulware 2014 reported that participants received between 7 and 11 days of antifungal therapy prior to randomization, and Zolopa 2009 also allowed for ≤ 14 days of antifungal treatment prior to randomization for ART initiation. Bisson 2013 randomized participants within 72 hours of antifungal therapy initiation, and Makadzange 2010 randomized participants at the time of cryptococcal meningitis diagnosis. Only one trial described providing supportive care in the form of electrolyte replacement, fluid management, and routine therapeutic lumbar punctures (Boulware 2014).
Antiretroviral therapy
Three trials reported using a combination of two nucleoside reverse transcriptase inhibitors including tenofovir, emtricitabine, zidovudine, and stavudine, and one non-nucleoside reverse transcriptase inhibitor, either efavirenz or nevirapine (Bisson 2013; Boulware 2014; Makadzange 2010), or protease inhibitor (Zolopa 2009).
Early ART
For early initiation of ART, all trials reported starting ART within two weeks of randomization (Bisson 2013; Boulware 2014; Makadzange 2010), with one trial initiating ART within 5 to 10 days (Bisson 2013), another within 1 to 2 weeks (Boulware 2014), and two trials initiating ART within 72 and 48 hours, respectively (Makadzange 2010; Zolopa 2009).
Delayed ART
Two trials reported initiating delayed ART around the one-month mark: Boulware 2014 (five weeks) and Bisson 2013 (32 days). Makadzange 2010 initiated delayed ART at a median of 10 weeks, and the delayed group in Zolopa 2009 initiated ART between 6 and 12 weeks after randomization.
Outcomes
Three trials reported on all-cause mortality at 6 to 12 months after randomization; we obtained additional data for this outcome directly from the authors of Makadzange 2010. 
Risk of bias in included studies
We evaluated the risk of bias of included trials for each of the six domains (see the 'Characteristics of included studies' tables). We did a graphical summary of the 'Risk of bias' assessment as represented in Figure 2 and Figure 3 . 
Allocation
Three of the four included trials adequately described random sequence generation and allocation concealment and were considered free of selection bias (Boulware 2014; Makadzange 2010; Zolopa 2009). One trial had an unclear risk of selection bias for both random sequence generation and allocation concealment, which were inadequately described (Bisson 2013).
Blinding
All four trials were open-label trials, that is participants and personnel were not blinded to treatment allocation group; we assessed these trials as having a high risk for performance bias. Outcome assessors were generally not blinded in the included trials for most outcomes. Two trials blinded IRIS outcome assessors (Boulware 2014; Zolopa 2009). We did not consider blinding an issue for mortality assessment and laboratory results, as these are objective outcomes, however adverse events and IRIS are fairly subjective. As a result, we assessed most trials as having an overall unclear risk of bias for outcome assessment.
Incomplete outcome data
The proportion of participants lost to follow-up was low (< 15%) in all trials. There was also no evidence of differential loss to followup. Zolopa 2009 only reported attrition for the total number of randomized participants and not specifically for those with cryptococcal meningitis; overall approximately 13% of participants were lost follow-up in this trial. We assessed all trials as at low risk of attrition bias.
Selective reporting
Two trials had published protocols that were available for assessment (Bisson 2013; Boulware 2014); these trials reported all relevant outcomes and were assessed as at low risk of reporting bias. We classified two trials as at unclear risk of bias for selective outcome reporting: Zolopa 2009 did not have a protocol available for assessment, and the protocol for Makadzange 2010 was only published after the trial was completed, and no prespecified outcomes were included in the published protocol.
Other potential sources of bias
One trial was at high risk of other potential sources of bias (Makadzange 2010). Some reported results were not arithmetically correct, which could have had an impact on effect estimates. In addition, the authors were not consistent with the intention-totreat approach, which could have affected the time-to-event analysis. Concerns about the results of this trial are echoed in comments from other trial authors in the same field, as referenced in the Characteristics of included studies tables.
Four trials with 294 participants contributed data to this comparison. See also Summary of findings for the main comparison for a summary of the overall results.
Primary outcomes
All-cause mortality at six to 12 months
There was higher mortality at this time point for those receiving early ART compared to those for whom ART was delayed (risk ratio (RR) 1.42, 95% confidence interval (CI) 1.02 to 1.97; 294 participants, 4 trials; I 2 = 13%; Analysis 1.1; Figure 4 ). The certainty of the evidence contributing to this outcome was low due to concerns regarding risk of bias and qualitative heterogeneity in the included trials and imprecision. We conducted a sensitivity analysis including only trials at an overall low risk of bias (Analysis 1.2). 
Secondary outcomes
Cryptococcal meningitis relapse
There was a trend towards a reduction in cryptococcal meningitis relapse with early ART compared to delayed ART. However, this effect did not reach statistical significance, as the CI included no effect (RR 0.27, 95% CI 0.07 to 1.04; 205 participants, 2 trials; I 2 = 0%; Analysis 1.3; Figure 5 ). The certainty of the evidence contributing to this outcome was low due to imprecision (few clinical events). 
Cerebrospinal fluid fungal clearance
Due to the variability in methods of reporting CSF fungal clearance, we could not pool the results from the two trials that reported on this outcome. We have presented these results narratively in Table 3 . Both trials found no difference in the rate of CSF fungal clearance between the two trial arms.
Mortality hazard ratio
Due to considerable unexplained heterogeneity in the pooled effect estimate from the trials where hazard ratios were provided (237 participants, 3 trials; I 2 = 84%; Analysis 1.4), we did not metaanalyse this outcome.
Cryptococcal IRIS
There was a suggestion of an increased risk of cryptococcal IRIS associated with early ART (RR 3.56, 95% CI 0.51 to 25.02; 205 participants, 2 trials; I 2 = 54%; Analysis 1.5; Figure 6 ). However, the CI around this estimate was very wide and included no effect. The certainty of the evidence for this outcome was very low due to marked imprecision of the estimate, risk of bias, and indirectness related to the IRIS assessment. We explored the use of availablecase analysis for this outcome in a sensitivity analysis (Analysis 1.6, Figure 7 ). 
HIV virological suppression
There was little to no difference in virological suppression at 24 weeks with early ART compared to delayed ART (RR 0.93, 95% CI 0.72 to 1.22; 205 participants, 2 trials; I 2 = 0%; Analysis 1.7). The certainty of the evidence contributing to this outcome was very low due to high risk of bias and imprecision (few clinical events). We explored the use of available-case analysis for this outcome in a sensitivity analysis (Analysis 1.8; Figure 8 ). 
Length of hospital stay
No trials reported length of hospital stay as an outcome. Bisson 2013 reported only prolonged hospitalizations as 2 (15%) and 4 (29%) in early and delayed ART arms, respectively.
Adverse events
Adverse event measures were not reported consistently between trials, therefore these data could not be meta-analysed. Bisson 2013 reported that all 14 participants in the early ART arm and 13/ 14 participants in the delayed ART arm experienced at least one grade 3 to 5 adverse event. Boulware 2014 reported the cumulative incidence of grade 3 to 5 adverse events as 84% (95% CI 74% to 90%) in the early ART group and 84% (95% CI 75% to 91%) in the delayed ART group. Makadzange 2010 described one episode of desquamating skin rash related to nevirapine and that liver function tests remained normal throughout the trial. Zolopa 2009 did not report adverse events specifically for participants with cryptococcal meningitis.
Subgroup analyses
All-cause mortality by antifungal therapy
We subgrouped the primary outcome of all-cause mortality according to type of antifungal therapy used. Among trials where amphotericin B therapy was combined with fluconazole (Bisson 2013; Boulware 2014), there was substantial unexplained heterogeneity between trials (I 2 = 66%), and effect estimates were not pooled. A further trial treated cryptococcal meningitis with fluconazole monotherapy (Makadzange 2010); the results of this trial indicated that those who initiated ART early had higher mortality compared to those who initiated ART later (RR 1.57, 95% CI 1.02 to 2.42; 54 participants; Analysis 1.9). Zolopa 2009 did not specify which antifungal therapy was used (RR 0.85, 95% CI 0.08 to 8.44; 35 participants; Analysis 1.9) and showed no overall difference in mortality between the treatment arms.
Sensitivity analyses
All-cause mortality
We explored the effect of the intervention on all-cause mortality at six months by restricting the analysis to trials with low risk of bias for sequence generation, attrition, and other bias that could influence this outcome.
Only the Cryptococcal Optimal ART Timing (COAT) trial, Boulware 2014, contributed to this analysis. The results from this trial indicated a higher risk of mortality among those who initiated ART early compared to those who delayed ART (RR 1.50, 95% CI 1.02 to 2.21; 177 participants, 1 trial; Analysis 1.2).
Cryptococcal IRIS
Applying an available-case analysis (RR 2.97, 95% CI 0.38 to 23.25; Analysis 1.6: Figure 7 ) and applying a low (8%) or high (46%) occurrence of cryptococcal IRIS to the missing cases differentially in the best-case (RR 1.56, 95% CI 0.45 to 5.40) and worst-case scenarios (RR 3.73, 95% CI 0.37 to 38.07) only resulted in a lower or higher precision estimate. In all instances, the estimates included no effect, and CIs remained wide and included appreciable benefit and harm. These results are in keeping with the intention-to treat analysis suggesting that this approach was reasonable for the analysis of cryptococcal IRIS.
Virological suppression on ART
We compared the use of an available-case analysis and best-and worst-case scenarios to evaluate missing data for this outcome. This resulted in a persistent result of no difference in virological suppression at six months between groups in the available-case analysis (RR 1.10, 95% CI 0.96 to 1.27; Analysis 1.8; Figure 8 ).
For the best-case scenario, we assumed 89% virological suppression for those missing viral loads or who did not receive ART in the early ART group and 50% for those missing in the delayed ART group. This resulted in better virological suppression in the early ART group (RR 1.26, 95% CI 1.10 to 1.45). When we applied the worst-case scenario and assumed that those missing viral loads or who did not receive ART in the early ART group had 50% suppression and in the delayed ART group had 89% suppression, this resulted in better virological suppression in the delayed ART group (RR 0.84, 95% CI 0.72 to 0.96). This suggested that the missing data for virological outcomes could bias results for this outcome and led to a downgrading of this outcome in the GRADE assessment.
Certainty of the evidence
We used GRADE to indicate the level of confidence we have in the results. The certainty of the evidence was either low or very low for most outcomes.
Methodological quality
The overall methodological quality was unclear for most trials that contributed to the analyses, due predominantly to the lack of reporting on several 'Risk of bias' domains. We categorized Makadzange 2010 as at high risk of bias for three domains, and the inclusion of this trial in the mortality analyses resulted in downgrading for risk of bias for these outcomes. Due to the lack of blinding of IRIS outcome assessors in one trial, we downgraded the evidence that contributed to the IRIS analysis. Viral load analysis was not conducted for all participants who were randomized or who received ART; we downgraded the certainty of the evidence for this outcome, as it is possible that randomization was not maintained for the subgroup that was analysed for this outcome.
Consistency
We detected qualitative and quantitative heterogeneity in the analysis of mortality, which led to downgrading the certainty of the evidence for the all-cause mortality outcome and prevented pooling of the results of the mortality hazard ratio outcome. We explored the use of different antifungal regimens in a subgroup analysis and found substantial heterogeneity between the trials providing amphotericin B, reflecting differences between these trials that could not be explained. This inconsistency could be the result of differences in the trial setting and conduct, however it was not possible to fully account for this in subgroup analyses.
Indirectness
We downgraded the cryptococcal IRIS outcome for indirectness, as we considered IRIS assessment to be quite subjective even when case definitions are applied.
Imprecision
We downgraded all outcomes due to imprecision. There were overall few clinical events contributing to each analysis. In addition, several analyses had wide CIs including no effect and appreciable harm or benefit.
Four trials including a total of 294 participants evaluated early ART initiation compared to delayed ART initiation (Summary of findings for the main comparison). The trials were conducted between 2003 and 2011, and all included people from low-and middle-income countries. Two trials used amphotericin B and fluconazole for cryptococcal meningitis induction therapy; one trial used fluconazole monotherapy; and one trial did not report the induction therapy used. All trials were conducted in adults.
Primary outcomes
Overall, when we pooled results from the four included trials we found that early ART initiation may increase all-cause mortality at six to 12 months among HIV-positive adults with cryptococcal meningitis, with low-certainty evidence contributing to this metaanalysis. A sensitivity analysis restricted to trials at low risk of bias showed higher risk of mortality among those initiating ART early; this analysis included one high-quality trial (COAT trial), which was terminated early due to the higher mortality risk in the early ART group.
Secondary outcomes
There was low-certainty evidence suggesting that early ART initiation may reduce the occurrence of cryptococcal meningitis relapse. Two RCTs evaluating the risk of developing IRIS found a tendency towards increased risk of cryptococcal IRIS in the early ART group, however the very low-certainty evidence contributing to this outcome means that we cannot say whether early ART initiation increases or decreases cryptococcal IRIS events compared to delayed ART initiation. We are uncertain if early ART affects virological suppression at six months, as the evidence contributing to this outcome was of very low certainty. Adverse events were not reported consistently between trials, therefore could not metaanalyse this outcome. Conclusions from the authors of trials that assessed this outcome suggest no difference in grade 3 to 5 adverse events between the two treatment arms. Similarly, data from the two trials reporting on time to fungal clearance could not be pooled, and the authors of these trials concluded that there was no difference between early and delayed ART arms for this outcome.
Overall completeness and applicability of evidence
We found only a few small trials that evaluated early versus delayed ART initiation in HIV-positive people with cryptococcal meningitis. The trials were generally conducted in low-and middle-income countries and included only adult participants. The results from this review can therefore be generalized only to these groups. The overall low certainty of the evidence limits the conclusions that can be drawn from these analyses. However, the pooled results do suggest that early ART may increase all-cause mortality. We were restricted in the number of subgroup and sensitivity analyses that we could perform due to the limited number of included trials and participants. When we restricted analyses to trials at low risk of bias for the primary outcome, the analysis contained one trial (Boulware 2014); these results showed a higher risk of mortality among those who initiated ART early. In addition, two of the included studies with the highest numbers of participants and showing higher mortality with early ART were terminated early due to excessive mortality in the early ART group. One needs to consider whether effect estimates would be higher if these trials had larger samples. Only two trials reported using amphotericin B-based induction therapy, which is the standard of care for treatment of people with cryptococcal meningitis. Although fluconazole monotherapy is not routinely recommended, in many low-and middle-income countries this single agent may still be used, and so findings from this trial remain relevant to these settings. Immune reconstitution inflammatory syndrome has been implicated as the reason for higher mortality in those who initiate ART early. Unfortunately, we could draw no conclusions on the effect of early ART on IRIS occurrence based on the available data.
Certainty of the evidence
Overall, the certainty of the evidence contributing to all outcomes was low or very low. This was due to generally few clinical events and wide CIs around effect estimates. In addition, the poor methodological quality of some trials that contributed to the mortality, cryptococcal meningitis IRIS, and virological suppression analyses led to further downgrading of these outcomes.
Potential biases in the review process
We minimized selection bias by conducting an extensive literature search using a wide range of search terms and databases. Two review authors independently screened the search outputs and evaluated eligibility. In addition, we evaluated the reference lists of included papers and previous systematic reviews. We have detailed any changes made to the trial protocol after publication and after the review process began in the Differences between protocol and review section.
Agreements and disagreements with other studies or reviews
A previous Cochrane Review conducted by Njei 2013 included two of the four trials included in this review (Makadzange 2010; Zolopa 2009). They concluded that there was insufficient evidence to determine whether early ART had an effect on mortality and suggested that there was a higher risk of IRIS among those who initiated ART early. Although our review did show some evidence of higher risk of IRIS in the early ART group, the certainty of the evidence contributing to this outcome was very low. The additional trials that contributed to this updated review, and rigorous application of the GRADE tool, resulted in low-certainty evidence of higher mortality among those who initiated ART early. These findings contrast with cohort studies, which suggest no difference in mortality risk when comparing early ART to delayed ART (Table 1 ). This may reflect some level of selection bias for this outcome in cohort studies.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Despite the low certainty of the evidence, it appears that initiating antiretroviral therapy (ART) within four weeks of cryptococcal meningitis diagnosis increases the risk of mortality compared to delaying ART beyond four weeks. Clinicians and guideline developers need to seriously consider the severe nature of the potential harms of initiating ART early in HIV-positive people with cryptococcal meningitis. Findings from this Cochrane Review contributed to the formulation of the current World Health Organization (WHO) guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-positive adults, adolescents, and children (WHO 2018).
Implications for research
With this suggestion of a higher risk of mortality in HIV-posi-tive people with cryptococcal meningitis who initiate ART early, it is unlikely that more randomized controlled trials will be conducted that evaluate early versus delayed ART as an intervention in people with cryptococcal meningitis. Questions regarding how to best manage patients who develop cryptococcal meningitis soon after ART initiation were not addressed in this Cochrane Review and will become more relevant as rapid ART initiation becomes widespread. 
A C K N O W L E D G E M E N T S
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bisson 2013
Methods
Study design: open-label RCT Participants
Inclusion criteria: adults ≥ 21 years of age: HIV-positive, (positive enzyme-linked immunosorbent assay and/or a detectable (i.e. > 400 copies/mL) plasma viral load) ; India ink-positive cryptococcal meningitis; ART-naive, no past use of ART besides for prevention of mother-to-child transmission ≥ 6 months previously; could provide written informed consent; to initiate or had initiated amphotericin B ≤ 72 hours prior to enrolment; no antifungal use within the prior 14 • Fungal burden (median (IQR) log 10 CFU/mL): early ART 5.3 (4.2 to 5.7); delayed ART 4.8 (3.8 to 5.5)
• GCS (% with GCS < 15): early ART 24% ; delayed ART 30% Dropouts during study period: 1
Interventions
Duration of antifungal therapy prior to randomization: 7 to 11 days Antifungal therapy provided: induction therapy: 2 weeks amphotericin B (0.7 to 1.0 mg/kg/day) combined with fluconazole (800 mg/day) Followed by 800 mg of fluconazole per day for at least 3 weeks or until a CSF culture was sterile, followed by 400 mg of fluconazole per day thereafter, for a total consolidation period of at least 12 weeks. 
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk
The trial authors used a computer-generated, permuted-block randomization algorithm with blocks of different sizes in a 1:1 ratio, stratified according to site and the presence or absence of altered mental status at the time that informed consent was obtained Allocation concealment (selection bias) Low risk Sequentially numbered, opaque, sealed envelopes stored in a lockbox contained the randomization assignments for enrolled participants. Envelopes were opened after written informed consent had been obtained Blinding of participants and personnel (performance bias) All outcomes
High risk
This was an open-label trial.
Blinding of outcome assessment (detection bias) All outcomes
Unclear risk While clinical assessors were blinded for IRIS and mortality, assessment of adverse events was unblinded Incomplete outcome data (attrition bias) All outcomes
Low risk There were no cases of loss to follow-up.
Selective reporting (reporting bias) Low risk
The trial authors reported all outcomes of interest and all protocol outcomes
Other bias Low risk
We did not identify any other potential sources of bias.
Makadzange 2010
Methods
Study design: RCT Participants
Inclusion criteria: eligible participants were aged 18 years and HIV-positive. All participants had cryptococcal meningitis confirmed by positive results of India ink identification of Cryptococcus neoformans in the CSF or a CSF cryptococcal polysaccharide antigen (CrAg) test (CALAS; Meridian Diagnostics), or both. Participants residing in a 50-kilometre radius of Harare. Informed consent Exclusion criteria: previous diagnosis of or treatment for cryptococcal meningitis, currently receiving ART, receiving medications that affect the metabolism of fluconazole (especially rifampicin), pregnant or lactating, or a history of hepatic or renal dysfunction Number randomized: 54 Descriptive baseline data • Age (mean (SD) years): early ART -36.6 (±8.5); delayed ART -37.5 (±6.9) • Sex (% male): early ART 50%; delayed ART 54% • CD4 count (median (IQR) cells/µL): early ART 27 (17 to 69); delayed ART 51.5 (25 to 69.5)
• Fungal burden (CSF CrAg titre > 1:128 (n;%)): early ART 15 (65.2); delayed ART 21 (87.5)
• Level of consciousness at baseline: not reported Dropouts during study period: 8 (some numerical discrepancy in flow diagram, which suggests 6)
Interventions
Duration of antifungal therapy prior to randomization: 0 days -randomized at time of diagnosis and treatment initiation Antifungal therapy provided: fluconazole (800 mg once per day; Diflucan (Pfizer)), after 10 weeks reduced to a prophylactic dosage of 200 mg once per day. Where treatment failure was suspected (positive culture, positive India ink or persistently elevated CrAg titres), dosage was increased once again to 800 mg daily until CSF clear Supportive care: not described CSF pressure management: CSF hypertension reduced if clinically indicated or CSF pressure high at study visits where LPs were conducted ART regimen: fixed-dose combination of stavudine (30 mg twice per day) and lamivudine (150 mg twice per day), and nevirapine (200 mg twice per day, with a 200 mg oncedaily 2-week lead-in dose) Early ART: started within 72 hours of randomization Delayed ART: started after 10 weeks of antifungal therapy Adherence: adherence to fluconazole and ART: self reports and pill counts at each visit (not reported in outcomes)
Outcomes
Primary outcomes • All-cause mortality Secondary outcomes
• Time to death • Adverse events Timing of outcome assessment: observed at outpatient clinic at 2, 4, 8, and 10 weeks, then monthly. Liver function tests conducted 6 monthly up to 2 years. Cerebrospinal fluid sampled at weeks 2, 4, and 10
Notes
Country: Zimbabwe Setting: a tertiary referral teaching hospital in Harare Dates: October 2006 through April 2008 Funding: The AIDS Care Research in Africa (ACRiA) programme and the small grants funding programme from the Infectious Diseases Society of America Other:
• Study was terminated early by the data safety monitoring committee, and the optimal sample size was not achieved.
• Safety concerns with regard to administration of fluconazole in high dose and nevirapine and lack of regular LFT monitoring.
• Concerns about censoring.
• Participants were discharged from hospital within 1 week • Numerical inconsistencies in results
Risk of bias
Bias Authors' judgement Support for judgement
Low risk A computer-generated randomization schedule was used to assign participants to the early ART and delayed ART arms of the trial Allocation concealment (selection bias) Low risk The randomization sequence was concealed to the trial nurse who was responsible for participant enrolment using sealed envelopes
Blinding of participants and personnel (performance bias) All outcomes Blinding of outcome assessment (detection bias) All outcomes
Unclear risk
Outcome assessment was not reported as blinded. Trial did not report on IRIS. This is unlikely to bias results for mortality and laboratory tests, however bias could be introduced for adverse events Incomplete outcome data (attrition bias) All outcomes
Low risk Losses to follow-up low and similar in both arms (3 out of 28 and 3/5 out of 26 in early ART and delayed ART arms)
Selective reporting (reporting bias) Unclear risk Protocol not available for review; outcomes not listed on Clin-icalTrials.gov (protocol registered after trial was completed) clinicaltrials.gov/ct2/show/NCT00830856
Other bias High risk Some reported results were not arithmetically correct, which could have had an impact on effect estimates. In addition, the authors were not consistent with the intention-to-treat approach, which could have affected the time-to-event analysis. Concerns about the results of this trial are echoed in comments from other trial authors in the same field (Boulware 2010; Bicanic 2010; Grant 2010).
Zolopa 2009
Study design: open-label RCT Participants
Inclusion criteria: eligible participants were HIV-positive men or women 13 years of age or older, presenting with an AIDS-defining opportunistic infection or serious bacterial infection for which effective antimicrobial therapy was available and prescribed. To reflect clinical practice, the trial allowed presumptive and confirmed diagnoses as long as appropriate treatment for the opportunistic infection/bacterial infection had been initiated (cryptococcal disease was required to be confirmed). Participants in whom tuberculosis was diagnosed after randomization remained in the trial Exclusion criteria: people with or on treatment for tuberculosis were excluded. People were ineligible if they had received ART within 8 weeks prior to study entry, more than 31 days of any ART within 6 months prior to study entry, or more than 1 ART regimen on which they experienced treatment failure Unclear risk Number of participants lost to follow-up was not reported exactly, however the trial authors state: "Eighty-seven percent of subjects, 123 in each arm, were evaluable for the primary endpoint", suggesting that loss to follow-up was 13% or less, which is acceptable. It is difficult to comment specifically on par- NR Abbreviations: IQR: interquartile range; N: number of participants; NR: not reported; SD: standard deviation; AZT: Zidovudine; D4T: Stavudine 1 TDF: tenofovir; FTC: emtricitabine; EFV: efavirenz; NVP: nevirapine; 3TC: lamivudine; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor. 2 This trial reported results for participants with a variety of opportunistic infections and did not provide descriptive data specifically for those with cryptococcal meningitis. Abbreviations: CFU: colony forming units; CI: confidence interval; CSF: cerebrospinal fluid 1 The trial authors reported: "The median numbers of CSF CFU measurements for the control and intervention arms, respectively, were 3 (IQR, 2-4 [range, 1-9]) and 4 (IQR, 2-5 [range, 1-7]) (P = .2, rank-sum test). The generalized estimating equation regression coefficient for the intervention was 0.20 (95% CI, -.85 to 1.25), indicating that intervention subjects had a rate of CSF clearance that tended to be 0.20 log10 CSF CFU/mL/day slower than controls, although this difference was not significant." 2 The trial authors reported: "Similar rates of CSF culture positivity at 14 days (37% in the earlier-ART group and 39% in the deferred-ART group, P = 0.87). Among 59 participants with positive CSF cultures at 14 days, the median cryptococcal growth was 100 CFU per millilitre (interquartile range, 15 to 500), with no significant difference between treatment groups (P = 0.13); only 5 participants had more than 10,000 CFU per millilitre in CSF." (Continued) that there was a higher risk of IRIS among those who initiated ART early. This review update did show some evidence of higher risk of IRIS in the early ART group, but the certainty of the evidence contributing to this outcome was very low. The additional trials that contributed to this updated review, and rigorous application of the GRADE tool, resulted in lowcertainty evidence of higher mortality among those who initiated ART early 
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